New Drug Application Submitted for Once-Daily Baricitinib for RA Patients

New Drug Application Submitted for Once-Daily Baricitinib for RA Patients

A new drug application (NDA) has been submitted to the FDA for the approval of oral once-daily baricitinib (Eli Lilly/Incite Corporation) for the treatment of moderately to severely active rheumatoid arthritis (RA). Baricitinib is the only once-daily

(Visited 1 times, 1 visits today)
7
Like
Save

Comments

Comments are disabled for this post.